P's interim analysis is pushed back to Q3. I think that's

P's interim analysis is pushed back to Q3. I think that's part of the reasons for the sell-off today. My guess is the competition for patients are fierce from other psoriasis drugs, so Leo increased three more sites last month.

Quote:

I'm looking for the interim data for prurisol, supposed to be released 2nd quarter.